MedTrace Logo

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

NCT00939952 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2013-02-26

Study results available
· View outcomes & findings →

Summary

The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).

Conditions

Interventions

DRUG

ertapenem

500 mg IV once

Sponsors & Collaborators

Principal Investigators

  • Katie E Cardone, PharmD · Albany College of Pharmacy and Health Sciences

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939952 on ClinicalTrials.gov